# EDGAR Filing Document

**Accession Number:** 0001873093
**File Stem:** 0001493152-23-010063
**Filing Date:** 2023-3
**Character Count:** 2111
**Document Hash:** 47ebc9c56b2d9f379eaae5105773f5ed
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-010063.hdr.sgml**: 20230428

**ACCESSION NUMBER**: 0001493152-23-010063

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CytoMed Therapeutics Ltd
- **CENTRAL INDEX KEY:** 0001873093
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** U0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544
- **BUSINESS PHONE:** 603824911

**MAIL ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CytoMed Therapeutics Pte. Ltd.
- **DATE OF NAME CHANGE:** 20210716

**CytoMed Therapeutics Limited**

1 Commonwealth Lane #08-22

Singapore 149544

March 31, 2023

**<u>VIA EDGAR</u>**

U.S. SECURITIES AND EXCHANGE COMMISSION

Division of Corporation Finance, Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549

Attention: Tracie Mariner

Re: CytoMed Therapeutics Limited

Registration Statement on Form F-1

Originally Filed November 18, 2022

File No. 333-268456

Dear Ms. Mariner:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, CytoMed Therapeutics Limited (the "**Company**") hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m. on Friday, March 31, 2023, or as soon as thereafter practicable (the "**Effective Time**"). The Company hereby grants to each of Richard I. Anslow, Esq., Lijia Sanchez, Esq. and Kristina R. Brown, Esq. the authority to communicate to the staff of the U.S. Securities and Exchange Commission one or more requests for any potential deferral of the Effective Time.

---

| |
|:---|
| Very truly yours, |
| */s/ CHOO Chee Kong* |
| CHOO Chee Kong |
| Director and Chairman |

---